Alembic Pharmaceuticals, a Rs. 1,850 crore plus Vadodara based pharma major, has posted strong growth in profitability during the first quarter ended June 2014 and its net profit went up by 38.7 per cent to Rs. 64.67 crore from Rs. 46.64 crore in the corresponding period of last year. Its net sales moved up by 15.7 per cent to Rs. 493.65 crore from Rs. 426.59 crore. Its EPS improved to Rs. 3.43 from Rs. 2.47 in the last period.

The sales of branded formulations in India improved by 16 per cent to Rs. 223.28 crore from Rs. 191.97 crore. However, its generic sales in India declined by 5 per cent to Rs. 25.22 crore from Rs. 26.45 crore. Its sales of international branded formulations touched to Rs. 22.68 crore from Rs. 15.01 crore ad that of international generics improved by 33 per cent to Rs. 113.81 crore from Rs. 85.47 crore.

During the quarter, it filed 3 ANDAs taking cumulative ANDA filings to 64. It received approval for 3 ANDAs taking cumulative approvals to 35.